What Has Been the Progress and Growth of the Cholangiocarcinoma Market in Recent Years?
The cholangiocarcinoma market has seen considerable growth due to a variety of factors.
• In recent years, the market size for cholangiocarcinoma has seen swift expansion. It is expected to surge from $0.55 billion in 2024 to $0.63 billion in 2025, registering a compound annual growth rate (CAGR) of 13.4%.
The historic growth can be accredited to factors such as augmented incidence of liver and bile duct cancers, increased awareness regarding uncommon cancers, heightened emphasis on tailored treatments, a surge in the employment of immunotherapy methods, and a growing elderly population.
What Is The Expected Growth In The Cholangiocarcinoma Market?
The cholangiocarcinoma market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of cholangiocarcinoma is projected to experience swift expansion in the coming years, reaching a valuation of $1.02 billion by 2029. This signifies a compound annual growth rate (CAGR) of 13.1%.
The surge during the predicted period could be due to factors like the increased use of precision medicine, growing healthcare spendings, higher frequency of genetic testing, and the rising trend of retail pharmacies. Significant trends anticipated during this period comprise the progress in diagnostic methods, extending clinical trials, the incorporation of AI in diagnostics, improvements in drug delivery systems, broadening clinical trials, and advancements in drug research.
What Key Factors and Trends Are Driving The Growth Cholangiocarcinoma Market?
The surge in liver disease cases is anticipated to fuel the expansion of the cholangiocarcinoma market. Liver disease encompasses any conditions that disturb the standard function or form of the liver, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. The escalation in liver disease cases can be attributed to growing risk factors, including obesity, diabetes, alcohol intake, and viral hepatitis infections. Liver disease, especially chronic inflammation and cirrhosis, enhances the risk of cholangiocarcinoma by encouraging bile duct injury and malignant cell conversion. For example, the Office for Health Improvement and Disparities, a governmental agency in the UK, reported that in 2023, premature deaths due to alcoholic liver disease increased 3.6% to 5,984 from 5,776 in 2022. Consequently, the rise in liver disease incidence is stimulating growth in the cholangiocarcinoma market.
What Are The Primary Segments In The Global Cholangiocarcinoma Market?
The cholangiocarcinoma market covered in this report is segmented –
1) By Cancer: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
2) By Product: Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin
3) By Therapy: Targeted Drug Therapy, Chemotherapy, Immunotherapy
4) By Route Of Administration: Oral, Subcutaneous, Intravenous
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce
Subsegments:
1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma, Mass-Forming Intrahepatic Cholangiocarcinoma
2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma
Pre-Book The Cholangiocarcinoma Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Cholangiocarcinoma Market?
Leading companies involved in the cholangiocarcinoma market have directed their efforts towards developing innovative treatments such as targeted therapies, aiming to enhance the results of patient treatment. These targeted therapies are formulated to focus on particular genes, proteins, or molecules that aid in the growth of cancer cells. By delaying the processes that allow cancer to proliferate, these therapies endeavor to halt tumor growth, minimize side effects, and elevate the effectiveness of the treatment. For example, Taiho Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, introduced LYTGOBI (futibatinib), an FGFR inhibitor, in August 2023. This is meant for the treatment of inoperable biliary tract cancer with FGFR2 gene fusions. It is engineered to selectively and permanently inhibit FGFR signaling, thus helping to decelerate tumor growth and improve patient outcomes in iCCA cases that have advanced post-chemotherapy.
Who Are the Key Players In The Cholangiocarcinoma Market?
Major companies operating in the cholangiocarcinoma market are:
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boston Scientific Corporation
• Servier Laboratories. Incyte Corporation
• Exelixis Inc.
• Hutchison China MediTech Limited
• Zymeworks Inc.
• Agios Pharmaceuticals Inc.
• RenovoRx Inc.
• Specialised Therapeutics Pty Ltd
• Ascletis Pharma Inc.
• Tiziana Life Sciences Ltd.
• Taiho Pharmaceutical Co. Ltd.
What Is The Most Dominant Region In The Cholangiocarcinoma Market?
North America was the largest region in the cholangiocarcinoma market in 2024. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
